Overview

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
Aventis Pharmaceuticals
Roche Pharma AG
Treatments:
Capecitabine
Docetaxel